Join Immix Biopharma and key opinion leaders Heather Landau, MD (Director of Amyloidosis Program, Memorial Sloan-Kettering Cancer Center), Vaishali Sanchorawala, MD (Professor, Boston University School of Medicine), and Susan Bal, MD (Assistant Professor, University of Alabama at Birmingham) for a discussion of the current treatment paradigm for patients with relapsed/refractory AL Amyloidosis and the NEXICART-1 study of NXC-201 as a potential chimeric antigen receptor T (CAR-T) treatment option.

NXC-201 is a BCMA-targeted investigational CAR-T cell therapy in development for relapsed/refractory AL amyloidosis (ALA), relapsed/refractory multiple myeloma (R/R MM), with planned expansion into autoimmune indications. IMMX has demonstrated promising Phase 1/2a data in ALA, with a 100% overall response rate (9/9 heavily pre-treated patients), as well as a 95% overall response rate, with a median of 11.9 months of follow-up, in patients with R/R MM (36/38 heavily pre-treated patients). On November 21, 2023, IMMX announced receipt of IND clearance to expand NXC-201 dosing into the U.S. NXC-201 has been selected for an oral presentation and a poster presentation at the American Society for Hematology 65th Annual Meeting on December 10 and December 11, 2023.

NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma.